Insider · CIK 0001758790

Sablich Kim

Reports to the SEC for 3 companies · BRISBANE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001758790

Forms 4 and 5

Insider transactions

38 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-06-05	JAZZJazz Pharmaceuticals plcD Disposition to Issuer	EVP, GM of U.S.	DDisposition to Issuer	−2,082 sh	$129.73	−$270K	28,478
2023-03-08	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−1,752 sh	$139.42	−$244K	31,821
2023-03-08	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−1,261 sh	$140.19	−$177K	30,560
2023-03-05	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP, GM of U.S.	FTax Payment	−1,610 sh	$142.78	−$230K	33,573
2023-03-03	JAZZJazz Pharmaceuticals plcA Award	EVP, GM of U.S.	AAward	+10.4K sh	—	—	35,183
2023-03-01	Eiger BioPharmaceuticals, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+28K sh	—	—	28,000
2022-06-07	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−200 sh	$148.21	−$29.6K	26,995
2022-06-07	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−250 sh	$149.22	−$37.3K	26,745
2022-06-07	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−573 sh	$150.68	−$86.3K	26,172
2022-06-07	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−1,317 sh	$151.87	−$200K	24,855
2022-06-07	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−101 sh	$152.59	−$15.4K	24,754
2022-06-06	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP, GM of U.S.	FTax Payment	−1,759 sh	$149.25	−$263K	28,583
2022-06-06	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−1,388 sh	$152.15	−$211K	27,195
2022-03-11	Eiger BioPharmaceuticals, Inc.A Award	Director	AAward	+6,000 sh	—	—	6,000
2022-03-11	Eiger BioPharmaceuticals, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+12K sh	—	—	12,000
2022-03-05	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP, GM of U.S.	FTax Payment	−746 sh	$153.96	−$115K	30,342
2022-03-03	JAZZJazz Pharmaceuticals plcA Award	EVP, GM of U.S.	AAward	+9,953 sh	—	—	31,088
2021-11-11	JAZZJazz Pharmaceuticals plcS Sale	EVP, GM of U.S.	SSale	−2,748 sh	$135.01	−$371K	21,135
2021-06-05	JAZZJazz Pharmaceuticals plcF Tax Payment	EVP, GM of U.S.	FTax Payment	−1,452 sh	$176.47	−$256K	23,883
2021-04-23	Eiger BioPharmaceuticals, Inc.Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2021-02-25	JAZZJazz Pharmaceuticals plcA Award	EVP, GM of U.S.	AAward	+8,535 sh	—	—	25,335
2020-08-06	JAZZJazz Pharmaceuticals plcA Award	EVP, GM of U.S.	AAward	+16.8K sh	—	—	16,800
2020-08-06	JAZZJazz Pharmaceuticals plc · Incentive Stock Option (right to buy)A Award	EVP, GM of U.S.	AAward	+3,144 sh	—	—	3,144
2020-08-06	JAZZJazz Pharmaceuticals plc · Non-Qualified Stock Option (right to buy)A Award	EVP, GM of U.S.	AAward	+38.9K sh	—	—	38,856
2020-04-03	Myovant Sciences Ltd.A Award	Chief Commercial Officer	AAward	+87.8K sh	—	—	146,710
2020-04-03	Myovant Sciences Ltd.Employee Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+134K sh	—	—	134,464
2020-03-18	Myovant Sciences Ltd.S Sale	Chief Commercial Officer	SSale	−770 sh	$7.38	−$5,682.6	58,920
2020-03-18	Myovant Sciences Ltd.S Sale	Chief Commercial Officer	SSale	−15 sh	$6.93	−$103.95	58,905
2020-01-15	Myovant Sciences Ltd.S Sale	Chief Commercial Officer	SSale	−4,840 sh	$14.04	−$68K	59,690
2019-12-18	Myovant Sciences Ltd.S Sale	Chief Commercial Officer	SSale	−2,585 sh	$16.22	−$41.9K	64,530
2019-08-26	Myovant Sciences Ltd.A Award	Chief Commercial Officer	AAward	+37.4K sh	—	—	67,115
2019-08-26	Myovant Sciences Ltd.Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−134K sh	—	—	0
2019-08-26	Myovant Sciences Ltd.Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+134K sh	—	—	133,500
2019-08-26	Myovant Sciences Ltd.Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−66.1K sh	—	—	0
2019-08-26	Myovant Sciences Ltd.Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+66.1K sh	—	—	66,130
2019-04-05	Myovant Sciences Ltd.Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+66.1K sh	—	—	66,130
2018-12-17	Myovant Sciences Ltd.A Award	Chief Commercial Officer	AAward	+29.7K sh	—	—	29,700
2018-12-17	Myovant Sciences Ltd.Employee Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+134K sh	—	—	133,500

Recent filings

Accepted (ET)
Jun 74
Sablich Kim0001765581-23-000046
SEC(opens sec.gov)
Mar 104
Sablich Kim0001765581-23-000036
SEC(opens sec.gov)
Mar 74
Sablich Kim0001765581-23-000017
SEC(opens sec.gov)
Mar 34
Sablich Kim0001140361-23-010160
SEC(opens sec.gov)
Jun 84
Sablich Kim0001765581-22-000057
SEC(opens sec.gov)
Mar 114
Sablich Kim0001140361-22-009263
SEC(opens sec.gov)
Mar 94
Sablich Kim0001765581-22-000028
SEC(opens sec.gov)
Nov 154
Sablich Kim0001765581-21-000125
SEC(opens sec.gov)
Jun 94
Sablich Kim0001765581-21-000061
SEC(opens sec.gov)
Apr 234
Sablich Kim0001209191-21-028175
SEC(opens sec.gov)

Companies

Address

C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY

BRISBANE, CA, 94005